Why faster trials make participant understanding more important than ever
July 15, 2026 | Informed Consent, clinical trials, communication
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
“I was confused, didn’t understand half of what he was saying.” The clinician’s reply? “You’ll only retain 2% of what’s discussed.” Then they carried on. They didn’t go back.*
That isn’t how anyone should describe the conversation that determines whether they join a clinical trial. Regulatory reforms are removing unnecessary delays from study approval and start-up, but there’s one part of the process that can’t be compressed: ensuring people genuinely understand what they’re agreeing to.
Longer forms, same confusion
When consent comes up, the instinct is to add more: more detail, more pages, more risks spelled out. The result is documents that are comprehensive, yet largely unread.
One participant, three infusions into a cancer trial, put it plainly: “The list of potential side effects goes on for many pages. Before I could give informed consent, the risks were laid out in exacting detail. It’s hard to stay alert.”*
Patients who go looking for answers often come away with more questions. “I spent a night searching the internet and found nothing useful,” one wrote, “just terrifying statistics and medical jargon written for doctors.”*
These people weren’t asking for less information – they were asking for information they could actually understand. Because disclosure alone isn’t the same as understanding.
Consent is a conversation, not a signature
The problem isn’t always the consent form itself. Sometimes it’s what happens around it. A research coordinator, describing their own site, said the doctor “always pushes for them to sign the consent form without fully understanding the trial,” on the logic that “they’ll learn more as time goes on.” And if a participant asks to take the form home to read, or talk it over with their GP? That’s “looked at as a bad thing, since we might lose the patient.”*
That’s understandable when recruitment timelines are under pressure. But it’s also where informed consent can quietly become a process of collecting signatures rather than building understanding.
People need time to reflect, ask questions, involve family members or speak to healthcare professionals they trust. A signature doesn’t demonstrate understanding. A conversation does.
Clearer isn’t simpler
The goal of informed consent isn’t simply to disclose every possible piece of information. It’s to present information in a way people can understand, use, and act on – using plain language, structuring information logically, introducing visuals where they genuinely aid understanding, and layering information so participants can explore topics in more depth at their own pace.
And it has to work for everyone a trial hopes to reach: older participants, people with lower health literacy, caregivers deciding alongside a patient, and anyone moving between an app and a face-to-face conversation. None of that is a special accommodation. It’s just consent that works.
Why this matters more as trials speed up
Regulatory reforms such as Operation TrialBlazer, the EU Clinical Trials Regulation and the MHRA’s changes around proportionate, risk-based review are all designed to make clinical research more efficient, with faster timelines. That’s good news for patients waiting for new treatments.
Speed may shorten timelines, but it can’t shorten the responsibility to ensure genuine understanding. When people don’t fully understand what they’re joining, uncertainty doesn’t disappear after enrolment. It can resurface later as hesitation, withdrawal, missed assessments or poorer engagement throughout the study. Those challenges affect participant experience, recruitment, retention and ultimately the quality of the data a trial generates.
As trials become faster, understanding – not disclosure – becomes the measure of good consent.
Let’s talk
Clearer consent. Information people can actually use. Materials built for the full range of participants. If your study is picking up pace and you want the people in it to understand what they’re joining – and stay – let’s talk.
*We searched our index of patient and participant discussion for where people describe consenting to, or trying to understand, a clinical trial. The quotes are real, lightly edited for length, with identifying details removed. It’s a self-selected, anonymous source – illustrative, not statistically representative – but it shows, in patients’ own words, where consent is and isn’t working.
References
- US Department of Health and Human Services. Press release. Available here (accessed July 2026).
- Regulation (EU) No 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use (Clinical Trials Regulation).
- Health Research Authority. Clinical trials regulation reform. Available here (accessed July 2026).
- Health Research Authority. Informing participants and seeking consent. Available here (accessed July 2026).
- NHS England. Inclusive digital healthcare: a framework for NHS action on digital inclusion. Available here (accessed July 2026).
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Cuttsy+Cuttsy welcomes new team members
Cuttsy+Cuttsy is excited to announce the addition of three talented professionals to the team: Flo, an enthusiastic Account Executive; Vicki, a creative Graphic Designer; and Jo, a detail-driven Artworker
Designing with patients in mind: How to build more inclusive clinical trials
Discover how patient-centred design transforms inclusive clinical trials. Learn to overcome trial recruitment challenges by listening to patients and creating studies that fit real lives.
Why fresh patient voices are critical to improve clinical trials outcomes
Discover why diverse patient voices, especially first-time participants, are key to improving clinical trials. Boost recruitment, retention, and patient-centric research.
Using patient personas to add a personal touch to clinical trial recruitment and retention
Discover how patient personas can revolutionise clinical trial recruitment and retention. Personalise outreach, build trust, and improve patient engagement.
A month of insights: Key takeaways from May’s conferences
Explore key insights from some of May’s top healthcare conferences, covering patient engagement, health equity, co-creation, and tech innovation shaping clinical trials.
Cuttsy+Cuttsy and ISPEP highlight key patient insights in new clinical trials report
Explore how Cuttsy+Cuttsy and ISPEP are spotlighting patient engagement in clinical trials through a new global report.
Motivations that matter: Understanding clinical trial participation to create better research
Understanding why people join clinical trials is essential to improving recruitment and designing better research. Explores the diverse motivations driving participation — from altruism and hope for better health to…
Cuttsy+Cuttsy welcomes new team members and celebrates a familiar face returning
Cuttsy+Cuttsy proudly announces the expansion of its team with the addition of three new hires—Michelle, Jay, and Emily—and the welcome return of former team member Sally as Account Director.
AI and away we go: key insights from Reuters Pharma 2025
AI is revolutionising the pharmaceutical industry, as highlighted at Reuters Pharma 2025, with transformative applications across marketing, drug discovery, and patient engagement, despite challenges in adoption, regulation, and data trust.
Exciting updates from our content and strategy team
Cuttsy+Cuttsy celebrates new beginnings with the appointment of Oli Bailey as Strategy Director and recognises team excellence through several well-deserved promotions.